# Emerging evidence for the modulation of exocytosis by signalling lipids

Virginia García-Martinez, Yolanda Gimenez-Molina, José Villanueva, Frédéric D Darios, Bazbek Davletov, Luis M Gutierrez

► To cite this version:

Virginia García-Martinez, Yolanda Gimenez-Molina, José Villanueva, Frédéric D Darios, Bazbek Davletov, et al.. Emerging evidence for the modulation of exocytosis by signalling lipids. FEBS Letters, 2018, 592 (21), pp.3493 - 3503. 10.1002/1873-3468.13178. hal-01935292

HAL Id: hal-01935292

https://hal.sorbonne-universite.fr/hal-01935292

Submitted on 26 Nov 2018

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_2.png" /></figure>

REVIEW ARTICLE

# Emerging evidence for the modulation of exocytosis by
signalling lipids

Virginia Garcia-Martinez<fnref n="1" />, Yolanda Gimenez-Molina<fnref n="1" />, José Villanueva<fnref n="1" />, Frederic D. Darios<fnref n="2" />, Bazbek Davletov<fnref n="3" /> and Luis M. Gutiérrez<fnref n="1" />

**Correspondence**

L. M. Gutiérrez, Instituto de Neurociencias,
Universidad Miguel Hernández-CSIC, Sant
Joan d'Alacant, Alicante 03550, Spain
Fax: +34 965919561
Tel: +34 965919562
E-mail: luisguti@umh.es

(Received 27 April 2018, revised 1 June
2018, accepted 27 June 2018, available
online 10 July 2018)

doi:10.1002/1873-3468.13178

Edited by Wilhelm Just

Membrane fusion is a key event in exocytosis of neurotransmitters and hormones stored in intracellular vesicles. In this process, soluble N-ethylmaleimide sensitive factor attachment protein receptor (SNARE) proteins are essential components of the exocytotic molecular machinery, while lipids have been seen traditionally as structural elements. However, the so-called signalling lipids, such as sphingosine and arachidonic acid, interact with SNAREs and directly modulate the frequency and mode of fusion events. Interestingly, recent work has proved that the sphingosine analogue FTY-720, used in the treatment of multiple sclerosis, mimics the effects of signalling lipids. In the present Review, we discuss recent investigations suggesting that endogenous signalling lipids and synthetic analogues can modulate important physiological aspects of secretion, such as quantal release, vesicle recruitment into active sites, vesicle transport and even organelle fusion in the cytosol. Therefore, these compounds are far from being merely structural components of cellular membranes.

**Keywords:** exocytosis; signalling lipids; SNARE proteins

The fusion of the vesicles containing neurotransmitters and hormones with the plasma membrane to release their content during the process of exocytosis is a key event underlying the function of the neuronal and endocrine systems. In essence, this is a multisequential process involving the cytoskeletal-mediated transport of vesicles [1,2], their docking and final release of neurotransmitters through the interactions of soluble N-ethylmaleimide sensitive factor attachment protein receptor (SNARE) proteins and the lipids constituting the vesicular and plasma membrane [3,4].

The lipids within the membranes were initially assumed to play a passive role, but recent results

indicate that a class known as signalling lipids directly modulate SNARE function, and may play important roles in the physiology of neurosecretion [5-7].

Signalling lipids that modulate SNARE function include arachidonic acid (AA) and sphingosine. AA is generated from a variety of phospholipid molecules by phospholipase-A2 or diacylglycerol lipase whereas sphingosine is produced from sphingolipids. AA primarily seems to target t-SNARE protein syntaxin-1 [8,9], which is anchored to the plasma membrane, whereas sphingosine interacts with synaptobrevin, which is the complementary v-SNARE anchored to the vesicle. Both AA and sphingosine seem to enhance exocytosis

**Abbreviations**

PUFAs, polyunsaturated fatty acids; SMase, sphingomyelinase; SNAP-25, synaptosomal-associated protein of 25 kDa; SNARE, soluble N-ethylmaleimide sensitive factor attachment protein receptor.

<footnote n="1">1 Instituto de Neurociencias de Alicante, Consejo Superior de Investigaciones Científicas-Universidad Miguel Hernández de Elche, Sant Joan d'Alacant, Alicante, Spain</footnote>

<footnote n="2">2 Inserm, U1127, CNRS, UMR 7225, Institut du Cerveau et de la Moelle épinière, ICM, Sorbonne Université, Paris, France</footnote>

<footnote n="3">3 Department of Biomedical Sciences, University of Sheffield, UK</footnote>
of both neurotransmitters and hormones by promoting
formation of SNARE complexes [10].

Interestingly, a structural analogue of sphingosine of
fungal origin, FTY-720, also known as Fingolimod,
has been approved for the oral treatment of multiple
sclerosis [11], one of the most frequent disorders of the
CNS. In this case, this substance is phosphorylated
and binds to sphingosine-1-phosphate receptors, caus-
ing lymphocyte egress and immunosuppression, there-
fore being effective for the palliation of this CNS
inflammatory syndrome [12,13]. Nevertheless, this
drug, as it happens with signalling lipids, also
enhances SNARE complex formation and promotes
the release of neurotransmitters in neuroendocrine cel-
lular models [14]. Here, we review the molecular mech-
anisms and the exocytotic steps regulated by signalling
lipids and related molecules affecting the secretory
activity of neuronal and neuroendocrine cells.

The traditional and new role of lipids
in exocytotic membrane fusion

Neurotransmitters and hormones are stored in special-
ized vesicles. The release of these active substances
requires the fusion of the membrane forming these
vesicles with the plasma membrane during exocytosis
[15–17]. The process initiates with the formation of a
structure called the fusion pore, formed with lipids
from the opposite membranes [6,18,19].

As the formation of the fusion pore requires the
active reorganization of lipids to overcome energy bar-
riers, the actual ‘proteocentric’ vision claimed catalytic
proteins as sculptors of the lipid bilayers, giving the
lipids a mere passive structural role. Since lipid bilay-
ers need to adopt curved shapes during membrane
fusion, either proteins or lipids could help in the spon-
taneous bending, therefore the shape of the lipids
forming the fusing leaflets have an important role in
the facilitation of exocytosis [20]. In this sense, conic
shape lipids with larger or smaller heads comparing
with its inner fatty acid chains will facilitate membrane
curvature and in consequence there is a large number
of evidences supporting this ‘shaping’ role [7,20–23],
especially for lysophospholipids regulating the secre-
tion in neuroendocrine cells (see Fig. 1) [24,25].

Lipids can additionally influence exocytosis by
aggregating into specific microdomains that recruit
proteins required for neurosecretion. In this sense, it is
well-established that phosphatidyl inositol 4,5-bipho-
sphate (PIP2) is a specific requirement for exocytosis
(Fig. 1) [26], being recruited in secretory sites by intra-
cellular calcium elevations during cell stimulation [27].
Today, these initial studies have been supported by

recent studies proving that PIP2 coordinates the
translocation of secretory vesicles to their docking sites
on the plasma membrane in a Cdc42-dependent man-
ner [28,29]. In that way, forms clusters that, in addi-
tion to nucleation of the formation of F-actin bundles,
also interact with SNARE proteins [30], and in conse-
quence act as a beacon for vesicle guidance to active
secretory sites (Fig. 1).

In addition, other membrane constituents, such as
cholesterol, are essential for maintaining the hetero-
geneities in the plasma membrane that accumulate
secretory proteins such as syntaxin-1 in well-defined
clusters within so called lipid rafts [31–35].

Finally, lipids are incorporated into secretory pro-
teins to modify them and affect in that way either the
location or the activity. This post-translation modifica-
tion consists frequently in an acylation by the incorpo-
ration of palmitate, a saturated 16-carbon fatty acid,
into cysteine residues [36], and the major target in neu-
roendocrine cells is the SNARE protein synaptosomal-
associated protein of 25 kDa (SNAP-25) [37–39].
Palmitoylation of SNAP-25 in four central residues
(Fig. 1)[38], is likely to enhance the clustering of
SNAP-25 in cholesterol and sphingomyelin rich lipid
rafts and in that way may be a cohesive factor in the
formation of exocytotic active sites [33,40,41]. The
exact role of SNAP-25 palmitoylation is unclear, since
some studies indicate that it is a major factor support-
ing the secretory activity of this protein transmitting
to the fusing membranes the proper forces generated
during SNARE complex assembly or zippering [42],
whilst others suggest that the palmitoylation serves a
more conventional role in membrane anchoring [37].

It is important to mention that SNAP-25 is not the
only protein relevant for exocytosis that is pamitoy-
lated, as synaptobrevin 2, present in the vesicular
membrane could be modified by palmitic acylation
during brain development, as this modification is only
found in adults and not in embryonic rats [43]. In
addition, synaptotagmin 1, an essential calcium sensor
[44], is palmitoylated in five residues near the trans-
membrane domain [38]. Finally, cystein string protein
(CSP), a molecular chaperone helping in protein fold-
ing [45], is heavily palmitoylated in 14 cystein residues
and it has been found to be important for the secretory
process in neuronal and endocrine models [46–48].

As could be derived from the multiple roles assumed
by lipids as mentioned above, their function in exocy-
tosis is far more complex than the deduced from being
the basic structural elements forming membranes, and
this is further evidenced with recent data on the direct
modulation of the secretory machinery by signalling
lipids.
<figure><img src="image_3.png" /><figcaption>**Fig. 1.** Lipids regulate exocytosis by different mechanisms. This figure presents different ways used by lipids to regulate vesicle fusion during exocytosis. Lipids, such as lysophosphatidic acid present a conic shape that facilitate membrane curvature during exocytosis influencing this process in consequence (represented in green). In addition lipids could be incorporated into the proteins constituting the molecular machinery to for example stabilize membrane attachments as it happens with palmitoylation of SNAP-25, synaptobrevin, synaptotagmin, CSP and Rab proteins (in blue in the figure). Other lipids such PIP2 could be acting as molecular beacons for the guidance of the vesicles to secretory active sites (in yellow). Finally, signalling lipids could interact directly with SNARE proteins and promote vesicle fusion. This is the case of AA influencing syntaxin 1 activity or sphingosine facilitating an open conformation of synaptobrevin II and favouring SNARE complex formation (in red in the figure).</figcaption></figure>

## Signalling lipids, new players in the regulation of exocytosis

In neuroendocrine cells SNAREs proteins are located in the fluid mosaic of the plasma membrane composed of a diversity of lipids including phospholipids, sphingolipids and cholesterol [49], and stabilized by a matrix of cytoskeletal elements forming the dynamic cytoarchitecture of active sites [50,51]. In this environment, the activity of phospholipases could release either saturated and also polyunsaturated fatty acids (PUFAs) that normally are present in the sn-2 position [52], and often, the released PUFAs could act as a intracellular messengers regulating a diversity of cellular processes including exocytosis [25,53–57]. Specifically, phospholipase type A2 (PLA2) acting in the sn-2 site release lysophospholipids and free unsaturated fatty acids, and the latter ones can diffuse into cytosol

where they interact with their targets of action, likely in hydrophobic domains [58,59]. Certainly, different elements of the molecular machinery of exocytosis are among these targets, since it has been demonstrated that inhibitors of PLA2 influence exocytosis in neuroendocrine cells [57,60,61], and addition of snake PLA2 neurotoxins alter secretion in neuronal [62–65] and chromaffin cells [66,67] via a variety of mechanisms. In the latter secretory model, it is quite illustrative that other phospholipases such as phospholipase C (PLC) and phospholipase D (PLD) have been implicated in catecholamine secretion [68–71], in this cases the activation of PKC by diacylglycerol mediates the PLC pathway [70,72], whereas the generation of phosphatidic acid seems to be associated with PLD signalling driving the enhancement of exocytosis [68,69,71,73]. In all these cases the generation of a signalling lipid has been demonstrated to be essential to
influence different elements of the secretory pathway. From now on we will focus on the action of these compounds over the molecular constituents of the exocytotic molecular machinery.

## Signalling lipids interact directly with the fusion machinery

After the release of signalling lipids such AA or sphingosine from the lipid bilayer, these lipids could diffuse and interact with SNARE proteins and therefore regulate the activity of these fusogenic proteins. The first report of a direct interaction of signalling lipids with SNAREs was reported in 2005 when the direct administration of AA or the treatment with PLA2s was demonstrated to enhance the formation of the SNARE complex in synaptic membrane preparations [9]. One of the most remarkable characteristic of this potentiation is that AA could interact with syntaxin-1 even in the presence of Munc-18 which stabilizes a closed conformation of syntaxin-1 (Fig. 1) [8,9], this may suggest that this lipid could penetrate into the hydrophobic zones of syntaxin-1 without altering the native dimers of syntaxin-1/Munc-18. This may be a basic principle of AA activation of syntaxins since it was also reported to occur with the syntaxin-3 isoform [8].

The importance of this mechanism for the regulation of syntaxins was later stressed when we found that the protein α-synuclein, implicated in the phatogenesis of Parkinson's disease, was found to sequester AA preventing the enhancement of SNARE complex formation caused by this lipid [74], thus providing new insights into the alteration of neurotransmission by the pathogenic α-synuclein.

More recently, in screening the ability of a diversity of lipids in modulating the formation of SNARE complexes, we found that only sphingosine and some derivatives were able to activate synaptobrevin 2 to engage SNAP-25-syntaxin heterodimers acting in the interphase between vesicular lipids and synaptobrevin (Fig. 1) [10]. This effect was dose-dependent with a EC50 ~ 10 µM and resulted in the enhancement of the exocytosis in neuronal and neuroendocrine cellular models. Furthermore, in neurons from synaptobrevin 2 knockout mice no modulation of exocytosis by sphingosine was observed, thus stressing the implication of this vesicular SNARE in mediating the action of sphingosine activating neurosecretion [10]. Analysis of sphingosine-related compounds revealed two critical features of sphingosine to promote SNARE complex formation and enhance exocytosis: the length of the carbon chain and the positive charge of sphingosine. Furthermore, L-sphingosine was as active as the

D-sphingosine suggesting that it may act by perturbing the local environment of synaptobrevin [10].

In order to demonstrate that the endogenous sphingosine production could mimic these results, the activity of external sphingomyelinases (SMase) and intracellular ceramidases releasing sphingosine into the cytosol in isolated nerve terminals [10], or cultured chromaffin cells [54,75] was tested on potentiation of exocytosis. The obtained results support this mechanism and further implicate synaptobrevin 2 since the treatment of the cells with Botulinum Neurotoxin type D, cleaving vesicular synaptobrevin, prevented the enhancement of neurosecretion due to the production of sphingosine and derivatives.

It is important to note, however, that Camoletto and co-workers [76] found that sphingosine may act on syntaxin-1 facilitating the engagement with Munc-18. Thus, this mechanism will decrease the number of docked vesicles and increase paired-pulse facilitation in neurons.

In conclusion, there is substantial evidence for a direct interaction of signalling lipids with a variety of SNAREs and further work is needed to establish the precise molecular mechanisms involved in such interactions associated with the regulation of the secretory activity of neuronal and neuroendocrine cells.

## Signalling lipids increase the frequency and quantal release of neurotransmitters

How do signalling lipids affect the exocytotic process?. Well, if these lipid messengers potentiate the formation of SNARE complexes it is predicted that they will enhance secretion, and in the case of sphingosine, this has been demonstrated in melanotrophs, chromaffin cells, isolated nerve terminals and hippocampal neurons [10]. Since, exocytosis is a multistep process involving the translocation of vesicles to the plasma membrane, the ‘priming’ or maturation of the vesicles to be in a ‘ready-releasable’ state, and the final fusion of the membranes to release the vesicular content [15,17,77-79], it is important to define the different stages of this process altered by signalling lipids and this required the use of biophysical techniques with the capability of analysing fusion at the level of individual vesicles.

In 2013, two groups used such techniques to study the effect of sphingosine over the exocytosis in different cellular systems. Zorec's group from Ljubljana University applied the capacitance technique [80,81] to resolve unitary exocytotic events in pituitary lactotrophs finding that sphingosine increases the frequency of the fusion of small vesicles and also larger
dense vesicles [82]. They also observed that sphingosine promoted the full fusion of large vesicles whereas smaller vesicles tent to fuse in the 'kiss and run' mode [83], only partially releasing their vesicular content, leading to the conclusion that the vesicle size was an important factor favouring the shift of fusion mode caused by sphingosine.

Simultaneously, our group at the Institute of Neurosciences of Alicante performed experiments in adrenomedullary chromaffin cells, using the amperometry technique [84] to detect the release of catecholamines from individual fusion events by their oxidation at the tip of a carbon fibre [54]. In our study, sphingosine and derivatives were produced by SMase treatment of the cells, and resulted in the increase of the amount of catecholamines released in individual fusions with detection of changes in the kinetics of the process suggesting changes in the mode of fusion of the vesicles. In addition, AA was also employed to show a 2-3 fold increase in the amount of catecholamines release per individual event, again implying that in the control situation and with chromaffin cells stimulated by depolarization, the release is suboptimal (kiss and run mode) and that signalling lipids promoted the full granular fusion.

Later on, the whole cell and on-cell capacitance techniques were used to study if sphingomyelin derivatives affect the release of different types of vesicles in chromaffin cells [75], and the results demonstrated an increase in the frequency of the release of small vesicles as well as large dense granules in agreement with the results obtained in lactotrophs.

In conclusion, the experiments performed with techniques allowing the high temporal resolution of secretory events in neuroendocrine cells demonstrated that signalling lipids increase the frequency of fusion of clear small vesicles as well as large dense granules and that these lipids are able to favour a change in the mode of exocytosis from the transient fusion pore opening characteristic of the 'kiss and run' mode to the full extent fusion collapsing the vesicle membrane.

## FTY-720, an analogue of sphingosine revealed multiple possible targets for signalling lipids derivatives

The sphingolipid signalling pathway is important for the regulation of multiple physiological processes in the brain [85-89], including neurotransmission [52,90-92], and for the pathologies associated with neuronal disorders [88,93-95]. Therefore, molecules designed to mimic these compounds could interfere with the normal and pathological neuronal pathways and be useful as potential pharmacological tools. This is the case with

FTY-720 also known as Fingolimod, an analogue of sphingosine that has been used extensively as an immunosuppressant agent [96], and moreover, it has been recently approved for treatment of relapsing remitting multiple sclerosis [11,97]. FTY-720 crosses the blood brain barrier [98], and like sphingosine is phosphorylated, allowing it to interact with the receptors of sphingosine-1P mediating the egression of lymphocytes and causing immunosuppression (Fig. 2) [99].

Very recently it was demonstrated that FTY-720 readily imitates sphingosine in its ability to interact with synaptobrevin promoting SNARE complex formation and increasing exocytosis from neuronal and neuroendocrine cellular systems [14]. This drug at concentrations around 10-20 µM (very similar to the sphingosine range), was able to enhance the frequency of glutamate release from rat synaptosomes, secretion from melanotrophs and chromaffin cells, and the neurotransmission from cultured rat hippocampal neurons (Fig. 2). In addition, FTY-720, also shares with sphingosine the modulation of the mode of exocytotic fusion, as it augments the amount of neurotransmitter release per individual fusion event [14].

Nevertheless, FTY-720 could be having a complex action on secretion, as it has been found to inhibit the release of cargo from different types of vesicles in cultured rat astrocytes due to a decrease in vesicle mobility [100]. Both sphingosine and FTY-720, caused an impaired access of the vesicles to releasable sites, an effect that has been associated with an alteration of calcium dynamics by signalling lipids in this cellular system [101].

The results from astrocytes are in apparent contradiction with those reported in neuroendocrine systems, nevertheless, we have found recently that in chromaffin cells FTY-720 has a dual effect on catecholamine release. In this neuroendocrine model, incubation with FTY-720, increases the frequency of vesicle fusions during the first round of cell stimulation by depolarization but decreases the amount of vesicles recruited in subsequent stimulations, (V. Garcia-Martinez, J. Villanueva, Y. Gimenez-Molina & L. M. Gutiérrez, unpublished results). Furthermore, by using FRET, we have observed that FTY-720 interacts at the molecular level with SNARE clusters in chromaffin cells as was previously described for sphingosine and AA [54]. In addition, FTY720 could also interact with F-actin governing the motion of the vesicles in the close proximity of secretory sites [102,103]. Thus, FTY-720 seems to influence secretion through interaction with several cellular targets, and remarkably we have found recently by using electron microscopy that this compound also promotes the homotypic fusion of vesicles and the heterotypic fusion of vesicles and mitochondria in the
<figure><img src="image_4.png" /><figcaption>**Fig. 2.** Targets of the sphingomimetic drug FTY-720. The analogue of sphingosine FTY-720 was first characterized as an immunosuppressor drug when in its phosphorylated form binds to sphingosine 1-P receptors causing lymphocyte egress (A). This drug has been proved to mimic sphingosine activating synaptobrevin II and increasing the formation of the SNARE complex leading to the enhancement of neurosecretion (B). In addition, FTY-720 has been shown to inhibit the motion of the vesicles in astrocytes and chromaffin cells interacting with the F-actin cytoskeleton (C). Finally, and very recently, we have observed that FTY-720 could induce the homotypic fusion of vesicles and the heterotypic fusion of mitochondria with vesicles in the chromaffin cell cytosol (D, mixed organelles product of vesicle-mitochondria fusion).</figcaption></figure>

cytosol of chromaffin cells (Y. Gimenez-Molina, V. Garcia-Martinez, J. Villanueva, B. Davletov & L. M. Gutiérrez, unpublished results, Fig. 2), these intriguing findings may suggest that the characterization of the cellular targets of FTY-720 is an open research subject requiring further experimentation.

## Conclusions and perspectives

In conclusion, our understanding of the role of lipids in the process of the release of neurotransmitters and hormones by the exocytotic fusion of the vesicular and plasma membranes has evolved drastically in the last
20 years from being the mere structural components of
these membranes to a more active and direct function
in modulation of the proteins constituting the molecu-
lar machinery of membrane fusion. Today, it is well-
accepted that in addition to this structural role, certain
lipids such lysophospholipids could be helping to
adopt the membrane curvature favouring membrane
fusion [24,25], lipids such PIP2 are produced and
transported to the active sites to act as a molecular
beacons attracting vesicle movement towards these
specific sites for preferential fusion [30], and proteins
are modified by addition of palmitate chains to sup-
port membrane anchoring and stabilization [37].

Moreover, lipids such AA and sphingosine, pro-
duced by the action of phospholipases and diffusing
into the cytosol acting as signalling lipids have been
shown to interact with SNARE proteins and activate
the formation of the fusogenic SNARE complex there-
fore facilitating neurotransmission in neuronal and
neuroendocrine cells [8–10]. Interestingly, these lipids
modulate not only the frequency of vesicle fusion but
also the fusion pore behaviour promoting the full
fusion mode over the partial release by the ‘kiss and
run’ mode [54,82], thereby suggesting that these sig-
nalling lipids could be fine-tuning the amount of neu-
rotransmitter release per secretory event to adapt to
specific functional requirements.

The importance of these signalling lipids was stressed when FTY-720 (Fingolimod), a structural analogue of sphingosine was approved as the first drug for oral treatment of relapsing multiple sclerosis [11]. This therapeutic use is based on the immunosuppression properties of the phosphorylated form of FTY-720 binding to sphingosine 1-P receptors and suppressing lymphocyte egress [96]. In recent years, FTY-720 has been found to affect a plethora of physiological processes including neuronal gene expression, axonal growth, and regeneration [104], suggesting that this drug may influence a variety of aspects of the physiology of neurons. Therefore, the finding that FTY-720 mimics the properties of signalling lipids towards the activation of SNAREs and the parallel potentiation of exocytosis was fundamental to understand the possible mechanisms underlying the role of FTY-720 in neuronal function.

The results obtained with FTY-720 may indicate
that signalling lipids and related drugs could be acting
on multiple targets involved in different cellular and
pathological processes explaining why this compound
stimulates neuronal function and regeneration [104],
and benefits neuroprotection in murine disease models
[105], ischaemia [106,107], excitotoxicity [108], and can
even improve the recovery of memory and learning in
neurological disorders [109–112].

In summary, the study of the molecular mechanisms
associated with the physiological regulation of neu-
rosecretion by signalling lipids promises not only the
understanding of basic mechanisms governing the
secretory activity in neuronal and neuroendocrine cells
but also the possible design of new therapeutic agents
against neurological disorders.

Acknowledgements

This work was supported by grants from the Spanish
Ministerio de Economía y Competitividad (BFU2011-
25095 and BFU2015-63684-P, MINECO, FEDER,
UE) to LMG. We thank Dr. John F. Wesseling for
the careful reading and suggestions to improve the
manuscript.

References

1. Gutierrez LM (2012) New insights into the role of the cortical cytoskeleton in exocytosis from neuroendocrine cells. *Int Rev Cell Mol Biol* **295**, 109–137.

2. Trifaro JM, Gasman S and Gutierrez LM (2008) Cytoskeletal control of vesicle transport and exocytosis in chromaffin cells. *Acta Physiol (Oxf)* **192**, 165–172.

3. Burgoyne RD and Morgan A (1998) Analysis of regulated exocytosis in adrenal chromaffin cells: insights into NSF/SNAP/SNARE function. *BioEssays* **20**, 328–335.

4. Bennett MK and Scheller RH (1994) Molecular correlates of synaptic vesicle docking and fusion. *Curr Opin Neurobiol* **4**, 324–329.

5. Davletov B, Connell E and Darios F (2007) Regulation of SNARE fusion machinery by fatty acids. *Cell Mol Life Sci* **64**, 1597–1608.

6. Zimmerberg J, Curran M and Cohen FS (1991) A lipid/protein complex hypothesis for exocytotic fusion pore formation. *Ann N Y Acad Sci* **635**, 307–317.

7. Lang T, Halemani ND and Rammner B (2008) Interplay between lipids and the proteinaceous membrane fusion machinery. *Prog Lipid Res* **47**, 461–469.

8. Connell E, Darios F, Broersen K, Gatsby N, Peak-Chew SY, Rickman C and Davletov B (2007) Mechanism of arachidonic acid action on syntaxin-Munc18. *EMBO Rep* **8**, 414–419.

9. Rickman C and Davletov B (2005) Arachidonic acid allows SNARE complex formation in the presence of Munc18. *Chem Biol* **12**, 545–553.

10. Darios F, Wasser C, Shakirzyanova A, Giniatullin A, Goodman K, Munoz-Bravo JL, Raingo J, Jorgacevski J, Kreft M, Zorec R et al. (2009) Sphingosine facilitates SNARE complex assembly
and activates synaptic vesicle exocytosis. *Neuron* **62**, 683–694.

11 Strader CR, Pearce CJ and Oberlies NH (2011) Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite. *J Nat Prod* **74**, 900–907.

12 Ingwersen J., Aktas O., Kuery P., Kieseier B., Boyko A. and Hartung H. P. (2012) Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy. *Clin Immunol* **142**, 15–24.

13 Horga A and Montalban X (2008) FTY720 (fingolimod) for relapsing multiple sclerosis. *Expert Rev Neurother* **8**, 699–714.

14 Darios FD, Jorgacevski J, Flasker A, Zorec R, Garcia-Martinez V, Villanueva J, Gutierrez LM, Leese C, Bal M, Nosyreva E *et al*. (2017) Sphingomimetic multiple sclerosis drug FTY720 activates vesicular synaptobrevin and augments neuroendocrine secretion. *Sci Rep* **7**, 5958.

15 Almers W (1990) Exocytosis. *Annu Rev Physiol* **52**, 607–624.

16 Betz WJ and Angleson JK (1998) The synaptic vesicle cycle. *Annu Rev Physiol* **60**, 347–363.

17 Jahn R, Lang T and Sudhof TC (2003) Membrane fusion. *Cell* **112**, 519–533.

18 Lindau M and de Toledo GA (2003) The fusion pore. *Biochim Biophy Acta* **1641**, 167–173.

19 Monck JR and Fernandez JM (1994) The exocytotic fusion pore and neurotransmitter release. *Neuron* **12**, 707–716.

20 Kooijman E. E., Chupin V., Fuller N. L., Kozlov M. M., de Kruijff B., Burger K. N. and Rand P. R. (2005) Spontaneous curvature of phosphatidic acid and lysophosphatidic acid. *Biochemistry* **44**, 2097–2102.

21 Chernomordik L, Kozlov MM and Zimmerberg J (1995) Lipids in biological membrane fusion. *J Membr Biol* **146**, 1–14.

22 Chernomordik LV and Kozlov MM (2003) Protein-lipid interplay in fusion and fission of biological membranes. *Annu Rev Biochem* **72**, 175–207.

23 Kreutzberger AJB, Kiessling V, Liang B, Yang ST, Castle JD and Tamm LK (2017) Asymmetric phosphatidylethanolamine distribution controls fusion pore lifetime and probability. *Biophys J* **113**, 1912–1915.

24 Pan CY, Wu AZ and Chen YT (2007) Lysophospholipids regulate excitability and exocytosis in cultured bovine chromaffin cells. *J Neurochem* **102**, 944–956.

25 Amatore C, Arbault S, Bouret Y, Guille M, Lemaitre F and Verchier Y (2006) Regulation of exocytosis in chromaffin cells by trans-insertion of lysophosphatidylcholine and arachidonic acid into the

outer leaflet of the cell membrane. *ChemBioChem* **7**, 1998–2003.

26 Eberhard DA, Cooper CL, Low MG and Holz RW (1990) Evidence that the inositol phospholipids are necessary for exocytosis. Loss of inositol phospholipids and inhibition of secretion in permeabilized cells caused by a bacterial phospholipase C and removal of ATP. *Biochem J* **268**, 15–25.

27 Eberhard DA and Holz RW (1991) Calcium promotes the accumulation of polyphosphoinositides in intact and permeabilized bovine adrenal chromaffin cells. *Cell Mol Neurobiol* **11**, 357–370.

28 Wen PJ, Osborne SL, Zanin M, Low PC, Wang HT, Schoenwaelder SM, Jackson SP, Wedlich-Soldner R, Vanhaesebroeck B, Keating DJ *et al*. (2011) Phosphatidylinositol(4,5)bisphosphate coordinates actin-mediated mobilization and translocation of secretory vesicles to the plasma membrane of chromaffin cells. *Nat Commun* **2**, 491.

29 Wen PJ, Osborne SL and Meunier FA (2012) Phosphoinositides in neuroexocytosis and neuronal diseases. *Phosphoinositides Dis* **362**, 87–98.

30 Aoyagi K, Sugaya T, Umeda M, Yamamoto S, Terakawa S and Takahashi M (2005) The activation of exocytotic sites by the formation of phosphatidylinositol 4,5-bisphosphate microdomains at syntaxin clusters. *J Biol Chem* **280**, 17346–17352.

31 Chamberlain LH, Burgoyne RD and Gould GW (2001) SNARE proteins are highly enriched in lipid rafts in PC12 cells: implications for the spatial control of exocytosis. *Proc Natl Acad Sci USA* **98**, 5619–5624.

32 Lang T (2007) SNARE proteins and ‘membrane rafts’. *J Physiol* **585**, 693–698.

33 Salaun C, James DJ and Chamberlain LH (2004) Lipid rafts and the regulation of exocytosis. *Traffic* **5**, 255–264.

34 Lang T, Bruns D, Wenzel D, Riedel D, Holroyd P, Thiele C and Jahn R (2001) SNAREs are concentrated in cholesterol-dependent clusters that define docking and fusion sites for exocytosis. *EMBO J* **20**, 2202–2213.

35 Zhang J, Xue R, Ong WY and Chen P (2009) Roles of cholesterol in vesicle fusion and motion. *Biophys J* **97**, 1371–1380.

36 Baekkeskov S and Kanaani J (2009) Palmitoylation cycles and regulation of protein function (Review). *Mol Membr Biol* **26**, 42–54.

37 Gonzalo S and Linder ME (1998) SNAP-25 palmitoylation and plasma membrane targeting require a functional secretory pathway. *Mol Biol Cell* **9**, 585–597.

38 Veit M, Sollner TH and Rothman JE (1996) Multiple palmitoylation of synaptotagmin and the t-SNARE SNAP-25. *FEBS Lett* **385**, 119–123.
39 Hess DT, Slater TM, Wilson MC and Skene JH (1992) The 25 kDa synaptosomal-associated protein SNAP-25 is the major methionine-rich polypeptide in rapid axonal transport and a major substrate for palmitoylation in adult CNS. *J Neurosci* **12**, 4634–4641.

40 Puri N and Roche PA (2006) Ternary SNARE complexes are enriched in lipid rafts during mast cell exocytosis. *Traffic* **7**, 1482–1494.

41 Salaun C, Gould GW and Chamberlain LH (2005) Lipid raft association of SNARE proteins regulates exocytosis in PC12 cells. *J Biol Chem* **280**, 19449–19453.

42 Washbourne P, Cansino V, Mathews JR, Graham M, Burgoyne RD and Wilson MC (2001) Cysteine residues of SNAP-25 are required for SNARE disassembly and exocytosis, but not for membrane targeting. *Biochem J* **357**, 625–634.

43 Veit M, Becher A and Ahnert-Hilger G (2000) Synaptobrevin 2 is palmitoylated in synaptic vesicles prepared from adult, but not from embryonic brain. *Mol Cell Neurosci* **15**, 408–416.

44 Rizo J, Chen X and Arac D (2006) Unraveling the mechanisms of synaptotagmin and SNARE function in neurotransmitter release. *Trends Cell Biol* **16**, 339–350.

45 Chamberlain LH and Burgoyne RD (2000) Cysteine-string protein: the chaperone at the synapse. *J Neurochem* **74**, 1781–1789.

46 Brown H, Larsson O, Branstrom R, Yang SN, Leibiger B, Leibiger I, Fried G, Moede T, Deeney JT, Brown GR *et al.* (1998) Cysteine string protein (CSP) is an insulin secretory granule-associated protein regulating beta-cell exocytosis. *EMBO J* **17**, 5048–5058.

47 Evans GJ, Morgan A and Burgoyne RD (2003) Tying everything together: the multiple roles of cysteine string protein (CSP) in regulated exocytosis. *Traffic* **4**, 653–659.

48 Graham ME and Burgoyne RD (2000) Comparison of cysteine string protein (Csp) and mutant alpha-SNAP overexpression reveals a role for csp in late steps of membrane fusion in dense-core granule exocytosis in adrenal chromaffin cells. *J Neurosci* **20**, 1281–1289.

49 Holz RW and Senter RA (1985) Plasma membrane and chromaffin granule characteristics in digitonin-treated chromaffin cells. *J Neurochem* **45**, 1548–1557.

50 Torregrosa-Hetland CJ, Villanueva J, Giner D, Lopez-Font I, Nadal A, Quesada I, Viniegra S, Exposito-Romero G, Gil A, Gonzalez-Velez V *et al.* (2011) The F-actin cortical network is a major factor influencing the organization of the secretory machinery in chromaffin cells. *J Cell Sci* **124**, 727–734.

51 Villanueva J, Torregrosa-Hetland CJ, Gil A, Gonzalez-Velez V, Segura J, Viniegra S and Gutierrez LM (2010) The organization of the secretory machinery in

chromaffin cells as a major factor in modeling exocytosis. *HFSP J* **4**, 85–92.

52 Darios F, Connell E and Davletov B (2007) Phospholipases and fatty acid signalling in exocytosis. *J Physiol* **585**, 699–704.

53 Frye RA and Holz RW (1984) The relationship between arachidonic acid release and catecholamine secretion from cultured bovine adrenal chromaffin cells. *J Neurochem* **43**, 146–150.

54 Garcia-Martinez V, Villanueva J, Torregrosa-Hetland CJ, Bittman R, Higdon A, Darley-Usmar VM, Davletov B and Gutierrez LM (2013) Lipid metabolites enhance secretion acting on SNARE microdomains and altering the extent and kinetics of single release events in bovine adrenal chromaffin cells. *PLoS ONE* **8**, e75845.

55 Herrero I, Miras-Portugal MT and Sanchez-Prieto J (1992) PKC-independent inhibition of glutamate exocytosis by arachidonic acid in rat cerebrocortical synaptosomes. *FEBS Lett* **296**, 317–319.

56 Latham CF, Osborne SL, Cryle MJ and Meunier FA (2007) Arachidonic acid potentiates exocytosis and allows neuronal SNARE complex to interact with Munc18a. *J Neurochem* **100**, 1543–1554.

57 Morgan A and Burgoyne RD (1990) Relationship between arachidonic acid release and Ca2(+)-dependent exocytosis in digitonin-permeabilized bovine adrenal chromaffin cells. *Biochem J* **271**, 571–574.

58 Balsinde J, Winstead MV and Dennis EA (2002) Phospholipase A(2) regulation of arachidonic acid mobilization. *FEBS Lett* **531**, 2–6.

59 Winstead MV, Balsinde J and Dennis EA (2000) Calcium-independent phospholipase A(2): structure and function. *Biochim Biophys Acta* **1488**, 28–39.

60 Frye RA and Holz RW (1985) Arachidonic acid release and catecholamine secretion from digitonin-treated chromaffin cells: effects of micromolar calcium, phorbol ester, and protein alkylating agents. *J Neurochem* **44**, 265–273.

61 Frye RA and Holz RW (1983) Phospholipase A2 inhibitors block catecholamine secretion and calcium uptake in cultured bovine adrenal medullary cells. *Mol Pharmacol* **23**, 547–550.

62 Montecucco C and Rossetto O (2000) How do presynaptic PLA2 neurotoxins block nerve terminals? *Trends Biochem Sci* **25**, 266–270.

63 Rigoni M, Caccin P, Gschmeissner S, Koster G, Postle AD, Rossetto O, Schiavo G and Montecucco C (2005) Equivalent effects of snake PLA2 neurotoxins and lysophospholipid-fatty acid mixtures. *Science* **310**, 1678–1680.

64 Rigoni M, Schiavo G, Weston AE, Caccin P, Allegrini F, Pennuto M, Valtorta F, Montecucco C and Rossetto O (2004) Snake presynaptic neurotoxins with phospholipase A2 activity induce punctate swellings of
neurites and exocytosis of synaptic vesicles. *J Cell Sci* **117**, 3561–3570.

65 Rossetto O, Rigoni M and Montecucco C (2004) Different mechanism of blockade of neuroexocytosis by presynaptic neurotoxins. *Toxicol Lett* **149**, 91–101.

66 Giner D, Lopez I, Neco P, Rossetto O, Montecucco C and Gutierrez LM (2007) Glycogen synthase kinase 3 activation is essential for the snake phospholipase A2 neurotoxin-induced secretion in chromaffin cells. *Eur J Neurosci* **25**, 2341–2348.

67 Neco P, Rossetto O, Gil A, Montecucco C and Gutierrez LM (2003) Taipoxin induces F-actin fragmentation and enhances release of catecholamines in bovine chromaffin cells. *J Neurochem* **85**, 329–337.

68 Bader MF and Vitale N (2009) Phospholipase D in calcium-regulated exocytosis: lessons from chromaffin cells. *Biochim Biophys Acta* **1791**, 936–941.

69 Chasserot-Golaz S, Coorssen JR, Meunier FA and Vitale N (2010) Lipid dynamics in exocytosis. *Cell Mol Neurobiol* **30**, 1335–1342.

70 Creutz CE, Dowling LG, Kyger EM and Franson RC (1985) Phosphatidylinositol-specific phospholipase C activity of chromaffin granule-binding proteins. *J Biol Chem* **260**, 7171–7173.

71 Vitale N, Caumont AS, Chasserot-Golaz S, Du G, Wu S, Sciorra VA, Morris AJ, Frohman MA and Bader MF (2001) Phospholipase D1: a key factor for the exocytotic machinery in neuroendocrine cells. *EMBO J* **20**, 2424–2434.

72 Eberhard DA and Holz RW (1991) Regulation of the formation of inositol phosphates by calcium, guanine nucleotides and ATP in digitonin-permeabilized bovine adrenal chromaffin cells. *Biochem J* **279** (Pt 2), 447–453.

73 Vitale N (2010) Synthesis of fusogenic lipids through activation of phospholipase D 1 by GTPases and the kinase RSK2 is required for calcium-regulated exocytosis in neuroendocrine cells. *Biochem Soc Trans* **38**, 167–171.

74 Darios F, Ruiperez V, Lopez I, Villanueva J, Gutierrez LM and Davletov B (2010) Alpha-synuclein sequesters arachidonic acid to modulate SNARE-mediated exocytosis. *EMBO Rep* **11**, 528–533.

75 Garcia-Martinez V, Montes MA, Villanueva J, Gimenez-Molina Y, de Toledo GA and Gutierrez LM (2015) Sphingomyelin derivatives increase the frequency of microvesicle and granule fusion in chromaffin cells. *Neuroscience* **295**, 117–125.

76 Camoletto PG, Vara H, Morando L, Connell E, Marletto FP, Giustetto M, Sassoe-Pognetto M, Van Veldhoven PP and Ledesma MD (2009) Synaptic vesicle docking: sphingosine regulates syntaxin1 interaction with Munc18. *PLoS ONE* **4**, e5310.

77 Burgoyne RD, Morgan A, Robinson I, Pender N and Cheek TR (1993) Exocytosis in adrenal chromaffin cells. *J Anat* **183** (Pt 2), 309–314.

78 Jahn R (2004) Principles of exocytosis and membrane fusion. *Ann N Y Acad Sci* **1014**, 170–178.

79 Sudhof T. C. and Rizo J. (2011) Synaptic vesicle exocytosis. *Cold Spring Harb Perspect Biol* **3**, a005637.

80 Neher E and Marty A (1982) Discrete changes of cell membrane capacitance observed under conditions of enhanced secretion in bovine adrenal chromaffin cells. *Proc Natl Acad Sci USA* **79**, 6712–6716.

81 Lindau M and Neher E (1988) Patch-clamp techniques for time-resolved capacitance measurements in single cells. *Pflugers Arch* **411**, 137–146.

82 Flasker A, Jorgacevski J, Calejo AI, Kreft M and Zorec R (2013) Vesicle size determines unitary exocytic properties and their sensitivity to sphingosine. *Mol Cell Endocrinol* **376**, 136–147.

83 Alvarez de Toledo G, Fernandez-Chacon R and Fernandez JM (1993) Release of secretory products during transient vesicle fusion. *Nature* **363**, 554–558.

84 Wightman RM, Jankowski JA, Kennedy RT, Kawagoe KT, Schroeder TJ, Lesczyszyn DJ, Near JA, Diliberto EJ Jr and Viveros OH (1991) Temporally resolved catecholamine spikes correspond to single vesicle release from individual chromaffin cells. *Proc Natl Acad Sci USA* **88**, 10754–10758.

85 Kishimoto Y and Kawamura N (1979) Ceramide metabolism in brain. *Mol Cell Biochem* **23**, 17–25.

86 Bryan L, Kordula T, Spiegel S and Milstien S (2008) Regulation and functions of sphingosine kinases in the brain. *Biochim Biophys Acta* **1781**, 459–466.

87 Sonnino S and Prinetti A (2016) The role of sphingolipids in neuronal plasticity of the brain. *J Neurochem* **137**, 485–488.

88 Olsen A. S. B. and Faergeman N. J. (2017) Sphingolipids: membrane microdomains in brain development, function and neurological diseases. *Open Biol* **7**, 170069.

89 Hirabayashi Y (2012) A world of sphingolipids and glycolipids in the brain–novel functions of simple lipids modified with glucose. *Proc Jpn Acad Ser B Phys Biol Sci* **88**, 129–143.

90 Rao RP and Acharya JK (2008) Sphingolipids and membrane biology as determined from genetic models. *Prostaglandins Other Lipid Mediat* **85**, 1–16.

91 Verhage M (2005) Fatty acids add grease to exocytosis. *Chem Biol* **12**, 511–512.

92 Davletov B and Montecucco C (2010) Lipid function at synapses. *Curr Opin Neurobiol* **20**, 543–549.

93 Green P, Anyakoha N, Yadid G, Gispan-Herman I and Nicolaou A (2009) Arachidonic acid-containing phosphatidylcholine species are increased in selected brain regions of a depressive animal model:
implications for pathophysiology. *Prostaglandins Leukot Essent Fatty Acids* **80**, 213–220.

94 Fuller M. and Futerman A. H. (2018) The brain lipidome in neurodegenerative lysosomal storage disorders. *Biochem Biophys Res Commun*. https://doi.org/10.1016/j.bbrc.2018.03.042.

95 Brodowicz J, Przegalinski E, Muller CP and Filip M (2018) Ceramide and its related neurochemical networks as targets for some brain disorder therapies. *Neurotox Res* **33**, 474–484.

96 Kahan BD (1998) FTY720: a new immunosuppressive agent with novel mechanism(s) of action. *Transplant Proc* **30**, 2210–2213.

97 Brinkmann V (2009) FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. *Br J Pharmacol* **158**, 1173–1182.

98 Meno-Tetang GM, Li H, Mis S, Pyszczynski N, Heining P, Lowe P and Jusko WJ (2006) Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. *Drug Metab Dispos* **34**, 1480–1487.

99 Chiba K, Yanagawa Y, Masubuchi Y, Kataoka H, Kawaguchi T, Ohtsuki M and Hoshino Y (1998) FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. *J Immunol* **160**, 5037–5044.

100 Trkov S, Stenovec M, Kreft M, Potokar M, Parpura V, Davletov B and Zorec R (2012) Fingolimod-a sphingosine-like molecule inhibits vesicle mobility and secretion in astrocytes. *Glia* **60**, 1406–1416.

101 Stenovec M, Trkov S, Kreft M and Zorec R (2014) Alterations of calcium homoeostasis in cultured rat astrocytes evoked by bioactive sphingolipids. *Acta Physiol (Oxf)* **212**, 49–61.

102 Giner D, Lopez I, Villanueva J, Torres V, Viniegra S and Gutierrez LM (2007) Vesicle movements are governed by the size and dynamics of F-actin cytoskeletal structures in bovine chromaffin cells. *Neuroscience* **146**, 659–669.

103 Villanueva J, Torregrosa-Hetland CJ, Garcia-Martinez V, del Mar Frances M, Viniegra S and Gutierrez LM (2012) The F-actin cortex in chromaffin granule

dynamics and fusion: a minireview. *J Mol Neurosci* **48**, 323–327.

104 Anastasiadou S and Knoll B (2016) The multiple sclerosis drug fingolimod (FTY720) stimulates neuronal gene expression, axonal growth and regeneration. *Exp Neurol* **279**, 243–260.

105 Brunkhorst R, Vutukuri R and Pfeilschifter W (2014) Fingolimod for the treatment of neurological diseases-state of play and future perspectives. *Front Cell Neurosci* **8**, 283.

106 Hasegawa Y, Suzuki H, Sozen T, Rolland W and Zhang JH (2010) Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats. *Stroke* **41**, 368–374.

107 Nazari M, Keshavarz S, Rafati A, Namavar MR and Haghani M (2016) Fingolimod (FTY720) improves hippocampal synaptic plasticity and memory deficit in rats following focal cerebral ischemia. *Brain Res Bull* **124**, 95–102.

108 Cipriani R, Chara JC, Rodriguez-Antiguedad A and Matute C (2015) FTY720 attenuates excitotoxicity and neuroinflammation. *J Neuroinflammation* **12**, 86.

109 Wu H, Wang X, Gao J, Liang S, Hao Y, Sun C, Xia W, Cao Y and Wu L (2017) Fingolimod (FTY720) attenuates social deficits, learning and memory impairments, neuronal loss and neuroinflammation in the rat model of autism. *Life Sci* **173**, 43–54.

110 Miguez A, Garcia-Diaz Barriga G, Brito V, Straccia M, Giralt A, Gines S, Canals JM and Alberch J (2015) Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington's disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation. *Hum Mol Genet* **24**, 4958–4970.

111 Asle-Rousta M, Kolahdooz Z, Oryan S, Ahmadiani A and Dargahi L (2013) FTY720 (fingolimod) attenuates beta-amyloid peptide (Abeta42)-induced impairment of spatial learning and memory in rats. *J Mol Neurosci* **50**, 524–532.

112 Sun Y, Hong F, Zhang L and Feng L (2016) The sphingosine-1-phosphate analogue, FTY-720, promotes the proliferation of embryonic neural stem cells, enhances hippocampal neurogenesis and learning and memory abilities in adult mice. *Br J Pharmacol* **173**, 2793–2807.